… for directing site-specific A-to-I editing by endogenous ADAR enzymes Axiomer® platform applicability and potential in … that can direct site-specific deamination by endogenous ADARs (Adenosine Deaminases Acting on RNA). Rational EON …
This presentation reviews Axiomer editing oligonucleotides (EONs) structure activity, the potential of Axiomer platform as well as its applicability for the treatment of liver originated disorders.
… Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing LEIDEN, Netherlands & CAMBRIDGE, … granted patent JP 7244922 , which is related to the broad concept of using chemically modified oligonucleotides …
… ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. … of ProQR and a valued member of ProQR’s Scientific Advisory Board, where he has played an important role in shaping the Company’s ADAR-based RNA editing platform. Dr. Beal’s decades of …
Modification of a guide RNA can mimic the effect of hyperactive mutants and advance the approach of recruiting endogenous ADARs for site-directed RNA editing reported in Journal of the American Chemical Society (JACS) by Doherty EE et al.
Applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet
